natgillin/translations-raw huggingface dataset:
Co-administration of Atazanavir Krka with proton pump inhibitors is not recommended (see section 4.5).
Sočasna uporaba zdravila Atazanavir Krka in zaviralcev protonske črpalke ni priporočljiva (glejte poglavje 4.5).
Rifabutin AUC ↑48% (↑19% Rifabutin cmax ↑149% (↑103% Rifabutin cmin ↑40% (↑5% ↑87%)
Rifabutin AUC ↑48 % (↑19 % ↑84 %)** Rifabutin Cmax ↑149 % (↑103 % Rifabutin Cmin ↑40 % (↑5 % ↑87 %)** 25-O-dezacetil-rifabutin AUC ↑990 % 25-O-dezacetil-rifabutin Cmax ↑677 % 25-O-dezacetil-rifabutin Cmin ↑1045 %
None of the de novo substitutions (see Table 4) are specific to atazanavir and may reflect reemergence of archived resistance on atazanavir + ritonavir in Study 045 treatment-experienced population.
Razmerje spremembe dovzetnosti na celični kulturi v primerjavi z referenčnim divjim tipom je bilo določeno s testom PhenoSenseTM (Monogram Biosciences, South San Francisco, Kalifornija, ZDA) Nobena od novih substitucij (glejte preglednico 4) ni specifična za atazanavir in lahko kaže na ponoven pojav arhivirane odpornosti na atazanavir + ritonavir pri predhodno že zdravljenih bolnikih v študiji 045.
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 200 mg atazanavir (as sulphate).
Ena trda kapsula vsebuje 200 mg atazanavirja (v obliki sulfata).
Atazanavir AUC ↔0% (↓9% Atazanavir cmax ↑17% (↑8% Atazanavir cmin ↓42% (↓51%
Atazanavir (popoldan): vse skupaj s hrano Atazanavir AUC ↔0 % (↓9 % ↑10 %)* Atazanavir Cmax ↑17 % (↑8 % ↑27 %)* Atazanavir Cmin ↓42 % (↓51 % ↓31 %)*
The combination of rifampicin and atazanavir is contraindicated (see section 4.3).
Sočasna uporaba alfuzosina z atazanavirjem je kontraindicirana (glejte poglavje 4.3).
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 300 mg atazanavir (as sulphate).
Ena trda kapsula vsebuje 300 mg atazanavirja (v obliki sulfata).
Coadministration with atazanavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism.
Pri sočasni uporabi z atazanavirjem se lahko koncentracije zaviralca PDE5 povečajo in pojavijo njegovi neželeni učinki, kot so hipotenzija,
All patients HIV RNA <400 copies/ml, %
HIV RNA < 400 kopij/ml, % a
The recommended adult dose of Atazanavir Krka capsules is 300 mg once daily with 100 mg ritonavir once daily and with food, in combination with other anti-HIV medicines.
100 mg ritonavirja enkrat na dan in skupaj s hrano, v kombinaciji z drugimi zdravili proti HIV.
Hard gelatine capsule, size no. 00.
Trda želatinasta kapsula, velikost št. 00.
Hard gelatine capsule, size no. 0.
Trda želatinasta kapsula, velikost št. 0.
Hard gelatine capsule (capsule), size no. 00.
Trda želatinasta kapsula (kapsula), velikost št. 00.
ANTI-HCV AGENTS Grazoprevir 200 mg once daily (atazanavir 300 mg/ ritonavir 100 mg once daily)
ZDRAVILA ZA ZDRAVLJENJE OKUŽBE Z VIRUSOM HEPATITISA C Grazoprevir 200 mg enkrat na dan (atazanavir 300 mg/ ritonavir 100 mg enkrat na dan)
Human experience of acute overdose with atazanavir is limited.
Ni zadostnih izkušenj s prevelikim odmerjanjem atazanavirja pri človeku.
Mean urinary excretion of unchanged drug was 7% following 2 weeks of dosing at 800 mg once daily.
Povprečno izločanje nespremenjenega zdravila v urinu je bilo 7 %
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 150 mg atazanavir (as sulphate).
NAVEDBA ENE ALI VEČ UČINKOVIN Ena trda kapsula vsebuje 150 mg atazanavirja (v obliki sulfata).
Capsule shell of Atazanavir Krka 150 mg hard capsules Body: titanium dioxide (E171) gelatine
Ovojnica kapsule - Atazanavir Krka 150 mg trde kapsule Telo: titanov dioksid (E171) želatina
- Gallbladder problems uncommonly happen in people taking atazanavir.
- Pri osebah, ki jemljejo atazanavir, se občasno lahko pojavijo težave z žolčnikom.
If atazanavir is co-administered with irinotecan, patients should be closely monitored for adverse events related to irinotecan.
Če se atazanavir uporablja skupaj z irinotekanom, je toksičnost irinotekana lahko poveča.
- Atazanavir Krka may affect how well your kidneys work.
- Zdravilo Atazanavir Krka lahko vpliva na delovanje ledvic.
Capsule shell of Atazanavir Krka 300 mg hard capsules Body: titanium dioxide (E171) gelatine
Ovojnica kapsule - Atazanavir Krka 300 mg trde kapsule Telo: titanov dioksid (E171) želatina
Diltiazem AUC ↑125% (↑109% Diltiazem cmax ↑98% (↑78% Diltiazem cmin ↑142% (↑114%
Diltiazem AUC ↑125 % (↑109 % ↑141 %) Diltiazem Cmax ↑98 % (↑78 % ↑119 %) Diltiazem Cmin ↑142 % (↑114 % ↑173 %) Dezacetil-diltiazem AUC ↑165 % Dezacetil-diltiazem Cmax ↑172 % (↑144 % Dezacetil-diltiazem Cmin ↑121 % (↑102 %
Atazanavir AUC ↑7% (↓2% Atazanavir cmax ↑2% (↓4% ↑8%) Atazanavir cmin ↑15% (↑2% ↑29%) Elbasvir AUC: ↑376% (↑307% Elbasvir cmax: ↑315% (↑246% Elbasvir cmin: ↑545% (↑451%
Elbasvir AUC: ↑376 % (↑307 % ↑456 %) Elbasvir Cmax: ↑315 % (↑246 % ↑397 %) Elbasvir Cmin: ↑545 % (↑451 % ↑654 %)
Atazanavir AUC ↓87% (↓92%
Etinilestradiol AUC ↓19 % (↓25 %
Atazanavir, dosed 1 hr after ddI+d4T (fasted) Atazanavir AUC ↔3% (↓36% Atazanavir cmax ↑12% (↓33% Atazanavir cmin ↔3% (↓39%
Atazanavir AUC ↔3 % (↓36 % ↑67 %) Atazanavir Cmax ↑12 % (↓33 % ↑18 %) Atazanavir Cmin ↔3 % (↓39 % ↑73 %)
Lopinavir/ritonavirc (400 mg/100 mg twice daily) n=443
ATV/RTVb (300 mg/100 mg enkrat na dan) n = 120
As a general rule, it is recommended that HIV infected women not breast-feed their infants in order to avoid transmission of HIV.
Splošno priporočilo je, da ženske, okužene z virusom HIV,
The increase in progestin exposure may lead to related side-effects (e.g. insulin resistance, dyslipidemia, acne and spotting), thus possibly affecting the compliance.
Zaradi večje izpostavljenosti gestagenu se lahko pojavijo s tem povezani neželeni učinki (npr. odpornost proti insulinu,
Therefore, such coadministration is not recommended.
Uporabi takih kontraceptivov se je tako treba izogibati.
Cap: titanium dioxide (E171) yellow ferric oxide (E172) red ferric oxide (E172) gelatine ink:
Kapica: titanov dioksid (E171) rumeni železov oksid (E172)
- Kidney stones uncommonly happen in people taking atazanavir.
- Pri osebah, ki jemljejo atazanavir, se občasno lahko pojavijo ledvični kamni.
Atazanavir concentrations were greatly decreased when coadministered with didanosine (buffered tablets) and stavudine.
Pri sočasni uporabi z didanozinom (pufrane tablete) in s stavudinom so se koncentracije atazanavirja močno zmanjšale.
CD4 Mean Change from Baseline, cells/mm All patients
Srednja sprememba števila celic CD4 od izhodišča, celice/mm
EXPIRY DATE
občasni: dispneja
3rd Trimester (n=20)
Nova substitucija zaviralca proteaz (n = 35)
Atazanavir Krka should be discontinued if severe rash develops.
Atazanavir Krka prekiniti.
Atazanavir cmin: ↑713% (↑359%
Atazanavir AUC: ↑250 % (↑144 % Atazanavir Cmax: ↑120 % (↑56 % Atazanavir Cmin: ↑713 % (↑359 %
Capsule shell of Atazanavir Krka 300 mg hard capsules Body: titanium dioxide (E171) and gelatine
Ovojnica kapsule - Atazanavir Krka 150 mg trde kapsule: Telo:titanov dioksid (E171) in želatina
Capsule shell of Atazanavir Krka 150 mg hard capsules:
Ovojnica kapsule - Atazanavir Krka 200 mg trde kapsule:
The mechanism of amiodarone or systemic lidocaine/atazanavir interaction is
Mehanizem interakcije med amiodaronom in sistemskim lidokainom ter atazanavirjem je zavrtje CYP3A.
Buprenorphine, once daily, stable maintenance dose (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Metadon, stabilni vzdrževalni odmerek (atazanavir 400 mg enkrat na dan)
the clarithromycin/atazanavir interaction is CYP3A4 inhibition.
Mehanizem interakcije klaritromicin/atazanavir je zaviranje CYP3A4.
Atazanavir Krka may affect how well your kidneys work.
Zdravilo Atazanavir Krka lahko vpliva na delovanje ledvic.
Efavirenz 600 mg once daily (atazanavir 400 mg once daily with ritonavir 200 mg once daily)
Atazanavir (popoldan): vse skupaj s hrano na dan (atazanavir 400 mg enkrat na dan z ritonavirjem 200 mg enkrat na dan)
Irinotecan
Kinidin
If the combination is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded (see section 4.4).
- Če je potrebna uporaba dizoproksiltenofovirata ali antagonista receptorjev H2, je treba razmisliti o povečanju odmerka zdravila Atazanavir Krka na 400 mg z ritonavirjem 100 mg ob sočasnem spremljanju koncentracij zdravila (glejte poglavji 4.6 in 5.2).
Co-administration of atazanavir with triazolam or orally administered midazolam is contraindicated (see section 4.3), whereas caution should be used with co- administration of atazanavir and parenteral midazolam.
Sočasna uporaba atazanavirja s triazolamom ali peroralnim midazolamom je kontraindicirana (glejte poglavje 4.3).
Tenofovir disoproxil fumarate Cmin
Dizoproksiltenofovirjev fumarat AUC Dizoproksiltenofovirjev fumarat Cmax Dizoproksiltenofovirjev fumarat Cmin
Grazoprevir concentrations were greatly increased when coadministered with atazanavir/ritonavir.
Izjema sta bila le zlatenica in zvišanje vrednosti celotnega bilirubina, ki sta bila pri uporabi atazanavirja skupaj z ritonavirjem pogostejša.
Atazanavir Krka with ritonavir should be used with caution in patients with mild hepatic impairment.
Pri bolnikih z blago okvaro jeter je treba zdravilo Atazanavir Krka z ritonavirjem uporabljati previdno.
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with atazanavir.
Pri sočasni uporabi atazanavirja in antacidov, vključno z zdravili, ki vsebujejo pufre, se zaradi zvišanja vrednosti pH
Rare (may affect up to 1 in 1,000 people): - gait disturbance (abnormal manner of walking) - oedema (swelling) - hepatosplenomegaly (enlargement of the liver and spleen) - myopathy (aching muscles, muscle tenderness of weakness, not caused by exercise) - kidney pain
- hepatosplenomegalija (povečanje jeter in vranice); - miopatija (bolečina, občutljivost ali slabost mišic, ki ni posledica telesnega napora); - bolečine v ledvicah.
Proton pump inhibitors Omeprazole 40 mg once daily (atazanavir 400 mg once daily with ritonavir 100 mg once daily)
Omeprazol 40 mg enkrat na dan (atazanavir 400 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan)
Osteonecrosis
paragevzija
The efficacy of atazanavir /ritonavir in combination with
Zaradi zaviralnega učinka atazanavirja na
Further information on Nasym can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/nasym.
Nadaljnje informacije o zdravilu Nasym so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/nasym.
The European Medicines Agency decided that Nasym's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je odločila, da so koristi zdravila Nasym večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
This overview was last updated in May 2019.
Ta povzetek je bil nazadnje posodobljen 05-2019.
Nasym is a vaccine.
Zdravilo Nasym je cepivo.
Other information about Nasym
Druge informacije o zdravilu Nasym
What benefits of Nasym have been shown in studies?
Kakšne koristi zdravila Nasym so se pokazale v študijah?
An overview of Nasym and why it is authorised in the EU
Pregled zdravila Nasym in zakaj je odobreno v EU
Why is Nasym authorised in the EU?
Zakaj je zdravilo Nasym odobreno v EU?
Nasym received a marketing authorisation valid throughout the EU on 29 July 2019.
Zdravilo Nasym je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 29/07/2019.
When the animal comes into contact again with this or a similar virus, these antibodies together with other components of the immune system will be able to kill the viruses and help protect against the disease.
Ko je žival ponovno izpostavljena temu ali podobnemu virusu, ta protitelesa skupaj z drugimi mehanizmi imunskega sistema uničijo virus in pripomorejo k zaščiti pred boleznijo.
The most common side effect with Nasym (which may affect up to 1 in 10 animals) is a slight change in the consistency of the faeces.
Najpogostejši nezaželen učinek zdravila Nasym (ki lahko prizadene največ 1 žival od 10) je rahla sprememba v konsistenci iztrebkov.
What is Nasym and what is it used for?
Kaj je zdravilo Nasym in za kaj se uporablja?
These studies involved non-vaccinated animals given a dummy vaccination and all animals were artificially exposed to bovine respiratory syncytial virus.
Te študije so vključevale necepljene živali, ki so bile cepljene s cepivom brez učinkovine, vse živali pa so bile umetno izpostavljene bovinemu respiratornemu sincicijskemu virusu.
The withdrawal period for meat from cattle treated with Nasym is ‘zero' days, which means that there is no mandatory waiting time.
Karenca za meso goveda, zdravljenega z zdravilom Nasym, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
When an animal is given the vaccine, the animal's immune system recognises the virus as ‘foreign' and makes antibodies against it.
Ko žival prejme cepivo, imunski sistem prepozna virus kot „tujek“ in proti njemu tvori protitelesa.
For cattle from 9 days of age, the vaccine is sprayed into each of the animal's nostrils using an intranasal applicator.
Govedu od devet dni starosti se cepivo naprši v vsako nosnico z intranazalnim aplikatorjem.
What are the risks associated with Nasym?
Kakšna tveganja so povezana z zdravilom Nasym?
The effectiveness of Nasym has been shown in 7 laboratory studies in which vaccination of cattle with Nasym, either using the nasal spray route or injection into the muscle, reduced both shedding of virus and signs of respiratory disease, such as increased rate of breathing, difficulty in breathing and watery or mucky eyes.
Učinkovitost zdravila Nasym so dokazali v sedmih laboratorijskih študijah, v katerih je cepljenje govedi z zdravilom Nasym v obliki nosnega pršila ali injekcije v mišico zmanjšalo tako izločanje virusa kot znake respiratorne bolezni, kot so pospešeno dihanje, oteženo dihanje, izcedek iz oči in vnete oči.
Nasym contains a strain of bovine respiratory syncytial virus that is weakened and does not cause the disease.
Zdravilo Nasym vsebuje sev bovinega respiratornega sincicijskega virusa, ki je oslabljen in ne povzroča bolezni.
Nasym (bovine respiratory syncytial virus vaccine, live) EMA/287041/2019
Zdravilo Nasym (cepivo proti bovinemu respiratornemu sincicijskemu virusu, živo) EMA/422471/2019
For the full list of side effects and restrictions of Nasym, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Nasym glejte navodilo za uporabo.
How does Nasym work?
Kako zdravilo Nasym deluje?
Nasym (bovine respiratory syncytial virus vaccine, live)
Zdravilo Nasym (cepivo proti bovinemu respiratornemu sincicijskemu virusu, živo)
For cattle from 10 weeks of age, the vaccine is given as a single injection into the muscle followed by a second injection into the muscle 4 weeks later.
Govedu od 10 tednov starosti se cepivo daje kot enkratna injekcija v mišico, druga injekcija v mišico pa se da štiri tedne pozneje.
Nasym contains bovine respiratory syncytial virus strain Lym-56.
Zdravilo Nasym vsebuje bovini respiratorni sincicijski virus, sev Lym-56.
How is Nasym used?
Kako se zdravilo Nasym uporablja?
The medicine can only be obtained with a prescription and is available as a lyophilisate (a freeze dried powder) and solvent to make either a nasal spray or an injection.
Zdravilo je na voljo v obliki liofilizata (praška, posušenega z zamrzovanjem) in vehikla, iz katerih se pripravi pršilo za nos ali injekcija.
Nasym reduces shedding of virus and respiratory signs such as raised breathing rate, difficulty breathing, watery eyes and runny nose.
Zdravilo Nasym zmanjša izločanje virusa in respiratorne znake, kot so pospešeno in oteženo dihanje, izcedek iz oči in nosu.
The studies confirmed the vaccine starts to be effective 3 weeks after both nasal vaccination and injection into the muscle, with effectiveness lasting 2 months after nasal vaccination and 6 months after injection into the muscle.
Študije so potrdile, da cepivo začne učinkovati tri tedne tako po nazalnem cepljenju kot po injekciji v mišico, učinkuje pa dva meseca po nazalnem cepljenju in šest mesecev po injekciji v mišico.
Revaccination is given by injection into the muscle 2 months after the initial vaccination and then every 6 months.
Revakcinacija se daje z injiciranjem v mišico dva meseca po začetnem cepljenju in nato vsakih šest mesecev.
The vaccine starts to be effective 3 weeks after vaccination into the muscle and protection lasts for 6 months.
Cepivo začne učinkovati tri tedne po cepljenju v mišico, zaščita pa traja šest mesecev.
Revaccination is given as a single injection into the muscle 6 months after the initial vaccination course and then every 6 months.
Revakcinacija se daje z injiciranjem v mišico šest mesecev po začetnem sklopu cepljenja in nato vsakih šest mesecev.
The vaccine starts to be effective 3 weeks after nasal vaccination and protection lasts for 2 months following vaccination.
Cepivo začne učinkovati tri tedne po nazalnem cepljenju, zaščita pa traja dva meseca po cepljenju.
Nasym is a vaccine used to protect cattle against bovine respiratory syncytial virus, a disease that affects their airways.
Zdravilo Nasym je cepivo, ki se uporablja za zaščito pred bovinim respiratornim sincicijskim virusom pri govedu.
These measures should help to protect the environment.
Ti ukrepi pomagajo varovati okolje .
This was observed in less than 10% of the cattle treated in clinical studies.
To so zasledili pri manj kot 10% goveda v kliničnih raziskavah.
The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs, although quantitatively there are differences.
Presnavljanje je kakovostno podobno pri podganah, mini prašičih, ljudeh, govedih in prašičih , količinsko pa se razlikuje.
Milk: 5 days
Mleko: 5 dni
1348 Louvain-la-Neuve BELGIUM
1348 Louvain-la-Neuve, BELGIJA
Treatment of calves with Contacera 20 minutes before dehorning reduces post-operative pain.
Zdravljenje telet z zdravilom Contacera 20 minut pred odstranitvijo rogov zmanjša pooperativno bolečino.
6.2 Major incompatibilities
6.2 Glavneinkompatibilnosti
For example, a horse weighing 400 kg will receive 16 ml of Contacera, a horse weighing 500 kg will receive 20 ml of Contacera, and a horse weighing 600 kg will receive 24 ml of Contacera.
Na primer, konj, ki tehta 400 kg, bo prejel 16 ml Contaceraa, konj, ki tehta 500 kg, bo prejel 20 ml Contaceraa in konj, ki tehta 600 kg, bo prejel 24 ml za Contaceraa.
5 mg. For the full list of excipients, see section 6.1.
5 mg Za celoten seznam pomožnih snovi glejte poglavje 6.1.
ATCvet code: QM01AC06.
(oksikami) Oznaka ATCvet: QM01AC06
Cattle: meat and offal: 15 days; milk: 5 days Pigs: meat and offal: 5 days
Govedo: meso in organi: 15 dni; mleko: 5 dni Prašiči: meso in organi: 5 dni
Contacera alone will not provide adequate pain relief during the dehorning procedure.
Samo zdravilo Contacera ne zagotavlja ustreznega lajšanja bolečine med postopkom odstranjevanja rogov.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 06/12/2012
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 06/12/2012
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 15/02/2014
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 15/02/2014
This is equivalent to 1 ml of Contacera per 25 kg body weight of horse.
To je enakovredno 1 ml Contaceraa na 25 kg telesne mase konja.
injection.
injekcija.
Laboratory studies in cattle have not produced any evidence for teratogenic, foetotoxic, or maternotoxic effects.
Z laboratorijskimi študijami na govedu niso bili dokazani teratogeni in fetotoksični učinki ter toksični učinki na mater.
Ethanol (96%) 159.8 mg
Etanol 96-odstotni 159,8 mg
6.1 List of excipients - Ethanol (96%) - Poloxamer 188 - Macrogol 400 - Glycine - Sodium hydroxide - Hydrochloric acid, concentrated - Meglumine - Water for injections
- etanol, 96-odstotni - poloksamer 188 - makrogol 400 - glicin - natrijev hidroksid - klorovodikova kislina, koncentrirana - meglumin - voda za injekcije
Cattle and pigs:
Govedo in prašiči:
5531 AE Bladel THE NETHERLANDS
Handelsweg 25, 5531 AE Bladel, NIZOZEMSKA
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
BESEDILO “ZDRAVILO SHRANJUJTE IZVEN DOSEGA IN POGLEDA OTROK”
The active substance in Contacera is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) 37/2010:
Učinkovina zdravila Contacera kot je navedena v tabeli 1(dovoljene snovi) priloge Uredbe Komisije (EU)
To be administered either mixed with a small quantity of food, prior to feeding, or directly into the mouth.
Zdravilo dajemo zamešano v majhno količino hrane pred hranjenjem ali v gobec.
Approximately 98% of meloxicam is bound to plasma proteins.
Porazdelitev Približno 98 % meloksikama se veže na beljakovine v plazmi.
For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculoskeletal disorders, oral suspensions of meloxicam may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection.
Pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih lahko uporabimo peroralno suspenzijo meloksikama v odmerku po 0,6 mg meloksikama na kilogram telesne mase za nadaljevanje zdravljenja 24 ur po injekciji.
THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only.
BESEDILO ''SAMO ZA ŽIVALI'' Samo za živali.
Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Ne uporabite pri konjih z obolenji prebavil, kot so zdraženost prebavil in krvavitve, pri motnjah delovanja jeter, srca ali ledvic in pri hemoragičnih obolenjih.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
6.6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Ne uporabite v primeru preobčutljivosti na učinkovino ali na katero koli pomožno snov.
In very rare cases loss of appetite, lethargy, abdominal pain and colitis have been reported.
V zelo redkih primerih se je pojavila izguba apetita, zaspanost, bolečine v trebuhu in kolitis.
Single I.M.
Enkratna i.m.
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Rok uporabnosti zdravila v pakiranju za prodajo: 3 leti
Uncommon adverse reactions include transient swelling at the injection site in horses, but resolves without intervention.
Občasni neželeni učinki pri konjih vključujejo prehodne otekline na mestu injiciranja, ki minejo brez posredovanja.
INDICATION(S) Read the package leaflet before use.
INDIKACIJA(E) Pred uporabo preberite navodila za uporabo.
PHARMACEUTICAL FORM Oral suspension
FARMACEVTSKA OBLIKA Peroralna suspenzija
People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
In the case of overdose symptomatic treatment should be initiated.
Pri prevelikem odmerjanju uvedemo simptomatsko zdravljenje.
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Po dajanju zdravila plastenko zaprite z zaporko in merilno brizgo pomijte s toplo vodo in posušite.